Shares in Finnish outsourcing specialist Pihlajalinna have crashed 25% on the news that the Finnish Competition and Consumer Authority (FCCA) has recommended that the country's Market Court block its takeover by CVC-backed competitor Mehilainen.
Brazilian listed HMOs (health management organisations) Hapvida Saude and Grupo Notre Dame Intermedica have resumed their M&A binge since July after a quiet second quarter, despite the pandemic continuing to rage throughout the country.
Sell-side advisors Perella Weinburg have shortlisted a dozen second-rounder bidders for Eugin, the global IVF arm of NMC Health, according to reports in Spain. A source tells HBI Eugin's recent figures have been significantly impacted by COVID - will it impact the valuation?
The Spanish private healthcare market has been one of Europe's most attractive for institutional investors of late with strong organic and inorganic growth opportunities. PWC Spain's deals leader for Healthcare & Pharma Jose Zarzalejos talks us through the drivers, movers and shakers in the six main sub-sectors: hospitals, imaging, oncology, care homes, IVF and dentistry.
Italian pharmacy group Hippocrates Holding has attracted interest from several potential buyers according to a source close to the company, who adds that the group needs significant investment for its expansion plans.
Potentially embarrassing details of the acquisition of CMA-Medina, the largest independent lab group in Belgium by French player Biogroup have emerged. Articles in the Belgian business press suggest massive gross margins and speculation that CMA sold for €1bn.
Multiple sources tell HBI that UK, Czechia and Poland-based ophthalmology platform Optegra is for sale. We take a look at the detailed figures behind the prospective sale, speculate as to price and buyers, and speak to an operator source about his view of the business.
HBI hears that PE-backed Dutch mental health provider Mentaal Beter is for sale, with both private equity and international sector operators interested. A local consultant tells us why this is an attractive buy.